Expected, actual and hypothetical savings from the entry of generic LDTB patches
| Expected expenditure on BuTrans | Actual expenditure on Butec | Hypothetical expenditure on generic LDTB patches | Case 1 scenario. Actual savings from the entry of Butec | Case 2 scenario. Expected savings from the entry of generic LDTB | Hypothetical savings from the entry of generic LDTB compared with the entry of Butec only | |
| February 2016 | £18 555 | £16 774 | £17 701 | £1781 | £854 | –£927 |
| $24 307 | $21 973 | $23 188 | $2333 | $1118 | –$1214 | |
| March 2016 | £10 916 | £9972 | £10 307 | £944 | £609 | –£335 |
| $14 300 | $13 063 | $13 502 | $1236 | $797 | –$438 | |
| April 2016 | £58 716 | £53 014 | £47 654 | £5702 | £11 062 | £5360 |
| $76 917 | $69 448 | $62 426 | $7469 | $14 491 | $7021 | |
| May 2016 | £366 998 | £332 344 | £285 061 | £34 653 | £81 937 | £47 284 |
| $480 767 | $435 370 | $373 429 | $45 395 | $107 337 | $61 942 | |
| June 2016 | £849 529 | £697 845 | £640 097 | £151 683 | £209 432 | £57 749 |
| $1 112 882 | $914 176 | £838 527 | $1 98 704 | $274 355 | $75 651 | |
| July 2016 | £1 342 649 | £1 118 900 | £979 928 | £2 23 747 | £362 721 | £138 974 |
| $1 758 870 | $1 465 759 | $1 283 705 | $2 93 108 | $475 164 | $182 055 | |
| August 2016 | £1 824 602 | £1 537 199 | £1 289 085 | £287 402 | £535 517 | £248 115 |
| $2 390 228 | $2 013 730 | $1 688 701 | $376 496 | $701 527 | $325 030 | |
| Overall | £4 471 965 | £3 766 048 | £3 269 833 | £705 917 | £1 202 132 | £496 220 |
| $5 858 274 | $4 933 522 | $4 283 481 | $924 751 | $1 574 792 | $650 048 |
LDTB, low-dose buprenorphine.